Evidence map›Paper›PMID 39901032›Full record

ArticleBone marrow transplantation2025

Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation.

Shigeo Fuji, Masahito Tokunaga, Koji Kato, Nobuaki Nakano, Takero Shindo, Junya Makiyama, Hidehiro Itonaga, Ayumu Ito, Tetsuya Eto, Jun Ishikawa and 12 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Shigeo FujiDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan. fujishige1231@gmail.com.ORCID http://orcid.org/0000-0001-5118-7950
Masahito TokunagaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.ORCID http://orcid.org/0000-0003-1296-9006
Koji KatoHematology, Oncology & Cardiovascular medicine, Kyushu University Hospital, Fukuoka, Japan.
Nobuaki NakanoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.ORCID http://orcid.org/0000-0001-9826-7616
Takero ShindoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-2085-6151
Junya MakiyamaDepartment of Hematology, Sasebo City General Hospital, Nagasaki, Japan.ORCID http://orcid.org/0000-0003-0883-2920
Hidehiro ItonagaTransfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.ORCID http://orcid.org/0000-0003-1438-3623
Ayumu ItoDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5681-6357
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Jun IshikawaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Yuta HasegawaDepartment of Hematology, Hokkaido University Hospital, Hokkaido, Japan.ORCID http://orcid.org/0000-0002-9925-2093
Kenji IshitsukaDepartment of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.ORCID http://orcid.org/0000-0002-7030-497X
Yukiyoshi MoriuchiDepartment of Hematology, Sasebo City General Hospital, Nagasaki, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Hokkaido, Japan.ORCID http://orcid.org/0000-0002-3631-244X
Yasuo MoriHematology, Oncology & Cardiovascular medicine, Kyushu University Hospital, Fukuoka, Japan.ORCID http://orcid.org/0000-0001-6425-1720
Youko SuehiroDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Ken TakaseDepartment of Hematology, National Hospital Organization Kyusyu Medical Center, Fukuoka, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University, Tochigi, Japan.ORCID http://orcid.org/0000-0002-4866-9307
Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.ORCID http://orcid.org/0000-0003-3864-0823
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan.ORCID http://orcid.org/0000-0003-4404-2870
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.ORCID http://orcid.org/0000-0002-5935-0385

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39901032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.